STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

26/08/2016


STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

Bad Vilbel, August 26, 2016 –

The shareholder meeting of STADA Arzneimittel AG has today resolved with 55.98 percent of the votes cast to remove the chairman of the supervisory board Dr. Martin Abend as a member of the company’s supervisory board with effect as of the conclusion of the shareholder meeting on 26 August 2016.
All four candidates proposed by the Supervisory Board for election to the Supervisory Board, Dr. Birgit Kudlek, Tina Müller, Dr. Gunnar Riemann and Rolf Hoffmann have been elected.
 
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de


Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de

Download in PDF format

Share:

Related Posts

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018
The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2018.
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer